vs
ARROWHEAD PHARMACEUTICALS, INC.（ARWR）与AdvanSix Inc.（ASIX）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是ARROWHEAD PHARMACEUTICALS, INC.的1.4倍（$359.9M vs $264.0M），ARROWHEAD PHARMACEUTICALS, INC.净利率更高（11.7% vs -0.8%，领先12.4%），ARROWHEAD PHARMACEUTICALS, INC.同比增速更快（10461.3% vs 9.4%），AdvanSix Inc.自由现金流更多（$36.1M vs $11.3M）
Arrowhead Pharmaceuticals是总部位于美国加利福尼亚州帕萨迪纳的上市生物制药企业，专注于通过RNA干扰（RNAi）作用机制开发创新药物，核心研发管线覆盖乙型肝炎、α-1抗胰蛋白酶缺陷相关肝病及心血管疾病的治疗领域。
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
ARWR vs ASIX — 直观对比
营收规模更大
ASIX
是对方的1.4倍
$264.0M
营收增速更快
ARWR
高出10451.9%
9.4%
净利率更高
ARWR
高出12.4%
-0.8%
自由现金流更多
ASIX
多$24.8M
$11.3M
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $264.0M | $359.9M |
| 净利润 | $30.8M | $-2.8M |
| 毛利率 | — | 7.6% |
| 营业利润率 | 15.5% | -0.7% |
| 净利率 | 11.7% | -0.8% |
| 营收同比 | 10461.3% | 9.4% |
| 净利润同比 | 117.8% | -892.9% |
| 每股收益（稀释后） | $0.22 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARWRASIX
| Q4 25 | $264.0M | $359.9M | ||
| Q3 25 | — | $374.5M | ||
| Q2 25 | — | $410.0M | ||
| Q1 25 | — | $377.8M | ||
| Q4 24 | — | $329.1M | ||
| Q3 24 | — | $398.2M | ||
| Q2 24 | — | $453.5M | ||
| Q1 24 | — | $336.8M |
净利润ARWRASIX
| Q4 25 | $30.8M | $-2.8M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $31.4M | ||
| Q1 25 | — | $23.3M | ||
| Q4 24 | — | $352.0K | ||
| Q3 24 | — | $22.3M | ||
| Q2 24 | — | $38.9M | ||
| Q1 24 | — | $-17.4M |
毛利率ARWRASIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 17.9% | ||
| Q1 24 | — | 0.9% |
营业利润率ARWRASIX
| Q4 25 | 15.5% | -0.7% | ||
| Q3 25 | — | -0.9% | ||
| Q2 25 | — | 7.7% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | -3.9% | ||
| Q3 24 | — | 7.5% | ||
| Q2 24 | — | 11.5% | ||
| Q1 24 | — | -7.0% |
净利率ARWRASIX
| Q4 25 | 11.7% | -0.8% | ||
| Q3 25 | — | -0.7% | ||
| Q2 25 | — | 7.7% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 5.6% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | -5.2% |
每股收益（稀释后）ARWRASIX
| Q4 25 | $0.22 | $-0.11 | ||
| Q3 25 | — | $-0.10 | ||
| Q2 25 | — | $1.15 | ||
| Q1 25 | — | $0.86 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | — | $0.82 | ||
| Q2 24 | — | $1.43 | ||
| Q1 24 | — | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $715.0M | $19.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $568.4M | $815.2M |
| 总资产 | $1.6B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARWRASIX
| Q4 25 | $715.0M | $19.8M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | — | $18.4M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | — | $17.3M | ||
| Q2 24 | — | $12.1M | ||
| Q1 24 | — | $20.6M |
股东权益ARWRASIX
| Q4 25 | $568.4M | $815.2M | ||
| Q3 25 | — | $818.2M | ||
| Q2 25 | — | $823.7M | ||
| Q1 25 | — | $794.4M | ||
| Q4 24 | — | $774.6M | ||
| Q3 24 | — | $766.4M | ||
| Q2 24 | — | $746.6M | ||
| Q1 24 | — | $713.2M |
总资产ARWRASIX
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.5M | $63.7M |
| 自由现金流经营现金流 - 资本支出 | $11.3M | $36.1M |
| 自由现金流率自由现金流/营收 | 4.3% | 10.0% |
| 资本支出强度资本支出/营收 | 0.8% | 7.7% |
| 现金转化率经营现金流/净利润 | 0.44× | — |
| 过去12个月自由现金流最近4个季度 | — | $6.4M |
8季度趋势，按日历期对齐
经营现金流ARWRASIX
| Q4 25 | $13.5M | $63.7M | ||
| Q3 25 | — | $26.6M | ||
| Q2 25 | — | $21.1M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $64.2M | ||
| Q3 24 | — | $57.3M | ||
| Q2 24 | — | $50.2M | ||
| Q1 24 | — | $-36.2M |
自由现金流ARWRASIX
| Q4 25 | $11.3M | $36.1M | ||
| Q3 25 | — | $66.0K | ||
| Q2 25 | — | $-7.2M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $29.8M | ||
| Q3 24 | — | $26.8M | ||
| Q2 24 | — | $16.7M | ||
| Q1 24 | — | $-71.6M |
自由现金流率ARWRASIX
| Q4 25 | 4.3% | 10.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | -1.7% | ||
| Q1 25 | — | -6.0% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 6.7% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | -21.3% |
资本支出强度ARWRASIX
| Q4 25 | 0.8% | 7.7% | ||
| Q3 25 | — | 7.1% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 9.0% | ||
| Q4 24 | — | 10.4% | ||
| Q3 24 | — | 7.7% | ||
| Q2 24 | — | 7.4% | ||
| Q1 24 | — | 10.5% |
现金转化率ARWRASIX
| Q4 25 | 0.44× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.67× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 182.29× | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARWR
暂无分部数据
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
